| Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin (NCT04502888) | Shattuck Labs, Inc. | 2020-09-17 |
| A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer (NCT04474470) | TyrNovo Ltd. | 2020-09-03 |
| Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) (NCT04428151) | Merck Sharp & Dohme LLC | 2020-08-06 |
| HYPORT: A Phase I/II Study of Hypofractionated Post-operative Radiation Therapy for Head and Neck Cancer (NCT04403620) | University of Texas Southwestern Medical Center | 2020-07-28 |
| A Study of Sigvotatug Vedotin in Advanced Solid Tumors (NCT04389632) | Seagen, a wholly owned subsidiary of Pfizer | 2020-06-08 |
| Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors (NCT04429542) | Bicara Therapeutics | 2020-06-01 |
| Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors (NCT04348916) | Oncorus, Inc. | 2020-05-20 |
| Navigation vs Usual Care for Timely Adjuvant Therapy for Patients With Locally Advanced HNSCC (NCT04030130) | Medical University of South Carolina | 2020-05-19 |
| Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors (NCT04344795) | Tempest Therapeutics | 2020-05-06 |
| Monitoring Blood Flow and Metabolic Activity in Malignant Tissue of Head and Neck Region (NCT04266470) | Wake Forest University Health Sciences | 2020-03-09 |
| A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer (NCT04144517) | Mural Oncology, Inc | 2020-02-05 |
| sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC (NCT04091867) | University of Colorado, Denver | 2020-01-06 |
| A Clinical Trial Evaluating TG4050 in Head and Neck Cancer (NCT04183166) | Transgene | 2019-12-12 |
| A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors (NCT03997968) | Cyteir Therapeutics, Inc. | 2019-10-09 |
| The Diagnostic Value of PET/MRI in Head and Neck Cancer (NCT04117139) | Odense University Hospital | 2019-10-01 |
| Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck (NCT04129320) | MacroGenics | 2019-10-01 |
| Navigation for Timely Adjuvant Therapy for Patients With Locally Advanced HNSCC (NCT04098458) | Medical University of South Carolina | 2019-09-12 |
| Analysis of Patterns of Recurrence in Head and Neck Cancer Using Clinicopathomic Markers (NCT04086849) | Sunnybrook Health Sciences Centre | 2019-07-30 |
| TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers (NCT03829436) | Tempest Therapeutics | 2019-03-20 |
| A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies (NCT03829501) | Kymab Limited | 2019-01-28 |
| NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy (NCT03589339) | Nanobiotix | 2019-01-16 |
| MGC018 With or Without MGA012 in Advanced Solid Tumors (NCT03729596) | MacroGenics | 2018-11-21 |
| A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck (NCT03576417) | Groupe Oncologie Radiotherapie Tete et Cou | 2018-10-10 |
| A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies (NCT03440437) | invoX Pharma Limited | 2018-04-16 |
| NIVolumab in Subjects With Recurrent or Metastatic Platinum-refrACTORy SCCHN (NCT05802290) | Gruppo Oncologico del Nord-Ovest | 2017-11-27 |
| A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms (NCT03219268) | MacroGenics | 2017-08-18 |
| Changes in Body Composition After EPA Supplementation in Head and Neck Patients (NCT02715596) | Institut Català d'Oncologia | 2015-12-23 |
| Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer (NCT02537223) | University Health Network, Toronto | 2015-09-01 |
| A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck (NCT02479178) | BIND Therapeutics | 2015-06-01 |
| Study to Evaluate the Response Rate to Therapy With Docetaxel and Cisplatin in Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck (NCT02061631) | Sanofi | 2014-05-01 |
| MicroRNA Markers in Head and Neck Cancers (NCT04305366) | University of Colorado, Denver | 2012-11-16 |
| A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer (NCT01598077) | Novartis Pharmaceuticals | 2012-07-01 |
| Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. (NCT01353625) | Celgene | 2011-04-25 |
| Pemetrexed as Salvage Treatment in Squamous Cell Carcinoma of Head and Neck (NCT01333696) | Fudan University | 2011-04-01 |
| Safety and Efficacy Study of P276-00 in Combination With Radiation in Subjects With Advanced Head and Neck Cancer (NCT00899054) | Piramal Enterprises Limited | 2009-08-01 |
| A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck (NCT00756444) | Amgen | 2008-10-21 |
| A Phase II Clinical Trial to Study the Efficacy and Safety of a New Drug P276-00 in Treatment of Recurrent and/or Locally Advanced Head and Neck Cancer (NCT00824343) | Piramal Enterprises Limited | 2008-09-01 |
| Dendritic Cell Vaccine for Head and Neck Cancer (NCT00492947) | University of Maryland, Baltimore | 2007-06-01 |
| Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck (NCT00459043) | Dana-Farber Cancer Institute | 2007-03-01 |
| A Study Of Lapatinib Versus Placebo Followed By Chemoradiation In Patients With Locally Advanced Head And Neck Cancer (NCT00371566) | GlaxoSmithKline | 2006-03-01 |
| Study of Docetaxel in Combination With Cisplatin and 5-Fluorouracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (NCT00139269) | Dana-Farber Cancer Institute | 1998-02-01 |